Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 456906 in NASH with Fibrosis (Phase II)
CTR20212081Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH), hepatic fibrosis, sponsored by Boehringer Ingelheim. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on CTR20212081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212081.